Table 1 Progression-free survival by subgroup
Patients (n, XVd vs Vd) | Median PFS, months (95% CI) | HR (95% CI) | P value | |
|---|---|---|---|---|
XVd | Vd | |||
1 prior line (99 vs 99) | 16.62 (13.24, NR) | 10.68 (7.26, 16.39) | 0.6295 (0.4133, 0.9586) | 0.0148 |
2–3 prior lines (96 vs 108) | 11.76 (7.39, NR) | 9.43 (6.83, 9.69) | 0.6949 (0.4760, 1.0147) | 0.0295 |
Lenalidomide naïve (118 vs 130) | 16.62 (12.98, NR) | 10.61 (8.44, 15.41) | 0.6619 (0.4548, 0.9634) | 0.0150 |
Lenalidomide treated (77 vs 77) | 9.59 (6.70, NR) | 7.23 (4.93, 9.69) | 0.6348 (0.4148, 0.9714) | 0.0177 |
PI naïve (47 vs 48) | NR (NR, NR) | 9.69 (8.44, NR) | 0.2585 (0.1116, 0.5988) | 0.0003 |
PI treated (148 vs 159) | 11.73 (7.95, 15.21) | 9.43 (7.06, 10.71) | 0.7839 (0.5791, 1.0612) | 0.0576 |
IMiD refractory (74 vs 86) | 13.93 (6.70, NR) | 8.44 (5.78, 9.56) | 0.5752 (0.3753, 0.8816) | 0.0051 |
Prior bortezomib only as induction for ASCT (37 vs 30) | 13.14 (11.73, NR) | 9.43 (5.75, NR) | 0.5807 (0.2860, 1.1791) | 0.0639 |
ASCT (76 vs 63) | 16.56 (9.59, NR) | 9.43 (5.91, 10.87) | 0.5527 (0.3411, 0.8955) | 0.0074 |
No ASCT (119 vs 144) | 13.24 (10.18, NR) | 9.56 (8.11, 13.60) | 0.7239 (0.5111, 1.0252) | 0.0341 |